Hydroxysafflor yellow a attenuates small airway remodeling in a rat model of chronic obstructive pulmonary disease

Biol Pharm Bull. 2014;37(10):1591-8. doi: 10.1248/bpb.b14-00198. Epub 2014 Jul 24.

Abstract

Our previous studies found that hydroxysafflor yellow A (HSYA), an active ingredient in Carthamus tinctorius L., has anti-inflammatory and anti-fibrosis properties. In this study, we investigated the effect of HSYA on small airway remodeling (SAR) in a chronic obstructive pulmonary disease (COPD) rat model induced by cigarette smoke and lipopolysaccharide (LPS). SAR is a common lesion in COPD characterized by thickening of the airway wall, mainly by subepithelial fibrosis. In this study the thickness of the small airway was determined by total wall area/basement membrane perimeter (WAt/Pbm). Collagen deposition of the small airway was assessed by Masson's trichrome staining. HSYA significantly attenuated the thickening and collagen deposition of the small airway and inhibited transforming growth factor β1 (TGF-β1) mRNA and protein expression in COPD rat. In addition, HSYA inhibited the phosphorylation of p38 mitogen-activated protein kinases (MAPK) in the lung tissue of rat. HSYA can attenuate experimentally induced airway remodeling and this attenuation may be attributed to suppression of TGF-β1 expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Airway Remodeling / drug effects*
  • Airway Remodeling / physiology
  • Animals
  • Chalcone / analogs & derivatives*
  • Chalcone / pharmacology
  • Chalcone / therapeutic use
  • Disease Models, Animal*
  • Male
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / pathology
  • Quinones / pharmacology*
  • Quinones / therapeutic use*
  • Rats
  • Rats, Wistar

Substances

  • Quinones
  • hydroxysafflor yellow A
  • Chalcone